Pathogenesis of primary biliary cirrhosis
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
rimary biliary cirrhosis (PBC) is a chronic cholestatic liver disease that affects up to one in 700 women in western populations (female to male ratio is approximately 10 to 1, with the disease typically presenting over the age of 40 years). 1 2 PBC is characterised histologically by damage to, and eventual loss of, the biliary epithelial cells (BEC) lining small intrahepatic bile ducts.BEC loss is typically accompanied by a significant portal tract inflammatory infiltrate that is mixed in phenotype (T cells (CD4 and CD8, with the latter predominating in the periductal areas), B cells, macrophages, eosinophils and natural killer cells).3 4 Early descriptions of PBC emphasised the predominant role played by the progression of bile duct loss, accompanied by increasing portal tract and linking fibrosis leading to biliary cirrhosis, in the clinical expression of PBC, and described an aggressive and uniformly fatal condition.5 Increased awareness of the condition and, in particular, the availability of diagnostic tools such as serology has led to broader and earlier diagnosis.6 This has had the effect that we now recognise PBC far more frequently than was previously the case, and typically do so at an earlier stage in the disease process.Broadening of the diagnostic base has, in addition, led us to appreciate that there is a significant subgroup within the PBC population who have a low risk of disease progression and who are unlikely to develop end-stage liver disease during a normal lifetime (but who remain at risk of developing the often life-altering symptoms of the disease such as fatigue, which are seemingly unrelated to the severity of the underlying liver disease).2 7 8 The factors that determine individual risk of disease progression remain unclear, precluding us, at present, from targeting disease-modifying therapies at ''high-risk'' patients.Study of the pathogenesis of PBC has focused, until relatively recently, almost entirely on immunological aspects of the disease.9 PBC was one of the first conditions in which the presence of autoantibodies in the serum was identified, and was one of the first conditions in which the antigen specificity of this autoreactive response was characterised. 3 This led, quite naturally, to the view that PBC is an autoimmune disease.This led, again not unreasonably (but largely unsuccessfully), to a focus on developing and applying therapies aimed at modifying this increasingly well-characterised autoreactive immune response.More recently, however, the true complexities of the processes seemingly contributing to PBC pathogenesis have begun to be appreciated and the exclusively autoimmune disease model has been challenged. PATHOLOGICAL FACTORS IN PBC cPBC pathogenesis from an immune system perspective PBC is characterised immunologically by the breakdown of immune self-tolerance to highly conserved mitochondrial and nuclear antigens (table 1). 3 10-19 The first autoreactive responses to be characterised in PBC were the serum antibody responses directed at antigens present on the inner mitochondrial membrane (antimitochondrial antibodies; AMA).AMA, which are present, often at very high titre, in over 95% of patients, are directed at the members of the 2-oxoacid dehydroganese complex family of multi-enzyme complexes.These complexes, which all play important roles in mitochondrial energetics, share a common multicomponent, multidomain structure.The dominant autoantibody response in PBC is directed at pyruvate dehydrogenase complex (PDC), although reactivity is seen to a lesser extent to all other 2-oxoacid dehydroganese complex family members (table 1).Within PDC, reactivity is seen, in particular, to the dihydrolipoamide acetyltransferase (E2) and enzyme 3 binding protein (E3BP) components.Reactivity is seen to these two antigens alone in over 90% of PBC patients.It was appreciated from relatively early on that the antibodies reactive with these two enzymes are fully crossreactive and that they can block the function of both enzymes.The mechanistic explanation for these two, in retrospect key, observations is the reactivity seen to a highly conserved structural motif present within both PDC-E2 and E3BP, 11 which consists of the binding domain for a lipoic acid (LA) co-factor that plays an essential role in enzyme function.The
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Afzali, B., Lombardi, G., Lechler, R. I., & Lord, G. M. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03356.x · Cited by 762 · cited 4×
“47 Development of the ‘‘Th17’’ cell subset (well characterised in the mouse and postulated to be present in the human) is induced in the joint presence of TGFb and IL-6, is suppressed by the actions of IL-2, and is associated with the reciprocal regulation of IFN-c.47 48 Although ‘‘Th-17’’ type CD4 T-cell function rem…”
BackgroundInfluentialPaumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748 · cited 1×
“Apoptosis can occur, however, as a direct consequence of the effects of hydrophobic bile salts known to be retained within the liver in PBC [56,57].”
BackgroundThe presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504
Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment
Selmi, C., Mayo, M. J., Bach, N., Ishibashi, H., Invernizzi, P., Gish, R. G., Gordon, S. C., Wright, H. I., Zweiban, B., Podda, M., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.05.005 · Cited by 480 · cited 1×
“This observation, together with a significantly increased incidence of PBC seen in the first-degree relatives of probands, would argue for a genetic component to PBC susceptibility.(83) 84 Moreover, the increased incidence of autoimmune disease in both PBC patients and their families would support this susceptibility…”
BackgroundSocial relationships, sleep quality, and interleukin-6 in aging women
Friedman, E. M., Hayney, M. S., Love, G. D., Urry, H. L., Rosenkranz, M. A., Davidson, R. J., Singer, B. H., & Ryff, C. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509281102 · Cited by 247
Kita, H., Matsumura, S., He, X.-S., Ansari, A. A., Lian, Z.-X., Van de Water, J., Coppel, R. L., Kaplan, M. M., & Gershwin, M. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214698 · Cited by 222
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites
Ala, A., Stanca, C. M., Bu-Ghanim, M., Ahmado, I., Branch, A. D., Schiano, T. D., Odin, J. A., & Bach, N. (2006) · Hepatology · doi:10.1002/hep.21076 · Cited by 222
Odin, J. A., Huebert, R. C., Casciola-Rosen, L., LaRusso, N. F., & Rosen, A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200110716 · Cited by 220
Familial primary biliary cirrhosis reassessed: a geographically-based population study
Jones, D. E., Watt, F. E., Metcalf, J. V., Bassendine, M. F., & James, O. F. W. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80097-x · Cited by 213
Self-citation
Cited by
Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis
The UK PBC Consortium, Mells, G. F., The Wellcome Trust Case Control Consortium 3, Floyd, J. A. B., Morley, K. I., Cordell, H. J., Franklin, C. S., Shin, S.-Y., Heneghan, M. A., Neuberger, J. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.789 · Cited by 464
Self-citationSelmi, C., Bowlus, C. L., Gershwin, M. E., & Coppel, R. L. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61965-4 · Cited by 334
Banales, J. M., Sáez, E., Úriz, M., Sarvide, S., Urribarri, A. D., Splinter, P., Tietz Bogert, P. S., Bujanda, L., Prieto, J., Medina, J. F., et al. (2012) · Hepatology · doi:10.1002/hep.25691 · Cited by 250
Novel therapeutic targets in primary biliary cirrhosis
Dyson, J. K., Hirschfield, G. M., Adams, D. H., Beuers, U., Mann, D. A., Lindor, K. D., & Jones, D. E. J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.12 · Cited by 120
Self-citationUnmet clinical need in autoimmune liver diseases
Dyson, J. K., Webb, G., Hirschfield, G. M., Lohse, A., Beuers, U., Lindor, K., & Jones, D. E. J. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.09.010 · Cited by 66
Self-citation
Metadata
- Authors
- Jones, D. E. J.
- Venue
- Postgraduate Medical Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-01-01
- Volume
- 84
- Issue
- 987
- Pages
- 23-33
- ISSN
- 0032-5473 (ISSN-L)
- 1469-0756
- OpenAlex
- W2114006962
- Cited by
- 115
- References
- 18
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathogenesis of primary biliary cirrhosis. https://app.cochat.ai/papers/10.1136/gut.2007.122150
- The paper
- Jones, D. E. J. (2008). Pathogenesis of primary biliary cirrhosis. Postgraduate Medical Journal. https://doi.org/10.1136/gut.2007.122150
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.